Kena Swanson VP of Pfizer Viral Vaccines said to the FDA:
“There is no established correlate of protection” between antibody levels and protection from COVID-19 disease.
Please share this so the truth gets out!
Ironically, FDA time and time again approves Pfizer and Moderna based on antibody titers. Don’t believe it?
Most recently FDA green lights Moderna and Pfizer’s bivalent BA 4/5 boosters based on immunogenicity data from 8 mice. To explain, immunogenicity data are lab metrics. They measure things like antibody levels.
Now the problem. A passing bar of antibody titers against a rapidly mutating RNA virus (SARS-CoV-2) is fundamentally flawed. Why? When the virus mutates, antibodies from mRNA vaccines no longer match their target. In other words, the antibodies are nearly ineffective. This needs to stop.
Case in point-here is a recent article I published:
We Are Officially Vaccinating People With Another Irrelevant mRNA Code
Updated CDC Nowcast data indicates new Omicron sublineages BQ.1 and BQ.1.1 make up 27.9% and 29.4% of all new infections respectively. That means, nearly 60% of the US population are infected from BQ.1 and BQ.1.1, but only 19.4% are infected from BA5.
Explain again why we are still giving bivalent BA5 boosters to people amid BQ.1, and BQ.1.1 dominance especially when protection against severe disease and death was mainly gained from prior infection and dose 1 anyway?
When will public health officials, and politicians understand chasing variants with mRNA vaccines is ineffective?
https://jamescintolo.substack.com/p/we-are-officially-vaccinating-people
What does all this mean? Well, if antibodies are a poor correlate of immunity, and Pfizer does not keep up with mutating strains, this seems to be a no brainer. The product is ineffective — stop producing it. Let’s not forget about the side effects.
Nonetheless, it is clear Pfizer does a terrible on the mRNA vaccine front. Therefore, one question remains. How do you feel about it?
LETS CONNECT:
Pfizer: “There is no established correlate of protection” between antibody levels and protection from disease